Navigation Links
PDL BioPharma Announces First Quarter 2009 Financial Results
Date:5/7/2009

nce as well as $0.9 million in software depreciation expense for which the software is now fully depreciated and is no longer in use.

Net income for the first quarter of 2009 was $37.5 million, or $0.23 per diluted share, compared with a net loss of $61.9 million in the same period of 2008, or a net loss of $0.42 per diluted share.

Net cash provided by operating activities was $27.7 million for the first quarter of 2009 as compared with net cash used in operating activities of $29.3 million for the first quarter of 2008. In addition to cash provided by operating activities in the three months ended March 31, 2009, we recognized $18.1 million of excess tax benefits from stock-based compensation, which is classified as a financing cash flow. At March 31, 2009, PDL had cash, cash equivalents, short-term investments and restricted cash of $193.2 million, compared with $147.5 million at December 31, 2008.

2009 Dividends

PDL previously announced that it would pay two dividends to its stockholders in 2009 of $0.50 per share. The first dividend, totaling $59.7 million, was paid on April 1, 2009 to all stockholders who owned shares of PDL on March 16, 2009. The second dividend will be paid on October 1, 2009 to stockholders of record on such date as to be determined by the Board of Directors at its June 2009 meeting.

Recent Developments

    -- Elected Frederick Frank and Jody Lindell to the Company's Board of
       Directors in March 2009 and subsequently designated Mr. Frank as Lead
       Director.

    -- As a result of the April 1, 2009 dividend payment, we announced
       An adjustment to the conversion rate for the Company's 2.75%
       Convertible Subordinated Notes due August 16, 2023 (the "2023 Notes").
       The conversion rate, as adjusted, is 123.715 shares of common stock per
       $1,000 principal amount of the 2023 Notes, effective 
'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sinobiopharma Secures Rights to Seven Key Patents
2. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
3. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Helix BioPharma to Present at the BioFinance 2009 Conference
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. 2009 Prix Galien USA Now Accepting Nominations for Top Prize in Biopharmaceutical Research and Development
8. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
9. Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry
10. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... PRC Clinical, a Silicon-Valley based ... and executive appointments effective immediately. , Mike Catelani will ... member of the Board of Directors. Daniel Head is ... Dowden will assume the position of Senior Director of ... Officer (COO), has been appointed to the position of ...
(Date:3/26/2015)... The Market Element LLC, a leading ... with Designing Gig LLC to provide website design, development, ... “Forging this alliance with Designing Gig represents a pivotal ... a comprehensive, end-to-end, digital solution for our clients, which ... Chuck Miller, president of The Market Element. “For small ...
(Date:3/26/2015)... LEXINGTON, Massachusetts and CINCINNATI ... Shire plc (LSE: SHP, NASDAQ: SHPG ... announced a three-year, broad research collaboration for rare ... and develop novel therapies to treat rare diseases ... and commercialization capabilities with Cincinnati Children,s research expertise. ...
(Date:3/26/2015)... , March 26, 2015 ... a global clinical research organization , ... a definitive agreement to acquire all of ... ("QSI"), a leading provider of specialized pharmacovigilance ... to the collection, detection, assessment, monitoring, and ...
Breaking Biology Technology:PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 2Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 3Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 4Shire and Cincinnati Children's Establish Rare Disease Research Collaboration 5PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... IRVING, Texas, Oct. 23 /PRNewswire-FirstCall/ -. Carrington,Laboratories, Inc. ... and raw material products, announced today that it,received ... are now being,traded on the OTC Bulletin Board ... market makers. The OTC Bulletin Board is ...
... N.J., Oct. 23 Collagen Matrix, Inc.,announces the ... orthopedic,and spine applications. OssiMend is an all-natural mineral-collagen,composite ... marrow,is used to fill bony voids or gaps ... OssiMend is conformable, non-friable, has a high,absorption capacity, ...
... Capital Joins Flagship Ventures Backing Leader in Fluorescence In ... ... VisEn Medical, Inc., a leader in,fluorescence in vivo imaging from ... Merck Capital Ventures,joined Flagship Ventures to co-lead this $7 million investment ...
Cached Biology Technology:Carrington Laboratories Common Stock Now Trading on the OTC Bulletin Board: CARN.OB 2Collagen Matrix, Inc. Launches OssiMend(TM) Bone Graft Matrix for Orthopedic and Spine Applications 2VisEn Medical Raises $7 Million in Series B Financing 2VisEn Medical Raises $7 Million in Series B Financing 3
(Date:3/10/2015)... --  Tute Genomics , pioneer in affordable, accurate and ... company PrimBio Research Institute to be its ... interpretation. PrimBio, a certified Life Technologies Ampliseq ... to support the work of experts on the front ... of exome sequencing services: 1) Targeted Exome and 2) ...
(Date:3/3/2015)... , March 3, 2015 Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... today announced the expansion of its relationship ... ("Fred Hutch") Clinical Research Division with ...
(Date:2/25/2015)... LITTLE ROCK, Ark. , Feb. 25, 2015 ... of software and billing in the Health and ... software as well as to MYiCLUBonline.  The latest ... MYiCLUBonline and the inclusion of cardless check-in via ... demonstrated for the first time through interactive displays ...
Breaking Biology News(10 mins):PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... Quebec City, September 12, 2011A study presented today by ... Medicine currently underway in Quebec City revealed that the risk ... which at least one member is an insomniac. ... Universit Laval,s School of Psychology, came to these conclusions following ...
... Findings, published today in Nature and Nature ... Genome-Wide Association Studies represent a major advance in our understanding ... potential therapeutic targets for prevention of heart disease and stroke ... published in Nature and co-led by scientists from ...
... time, USC scientists have mapped out a neuroreceptor. This ... used to treat ailments such as Alzheimer,s disease and ... images of the α7 (Alpha 7) receptor, a molecule ... regions of the brain believed to be associated with ...
Cached Biology News:Discovery of blood pressure genes could help prevent cardiovascular disease 2Discovery of blood pressure genes could help prevent cardiovascular disease 3USC scientists generate first detailed map of human neuroreceptor 2
...
Handy 100V Power Supply is Low-cost, compact and lightweight. Easy to operate - either 50 or 100 VDC is selectable as the output voltage. These voltages are sufficient for ordinary electrophoresis....
... power supply (Cat. No. Minis 150VS) is ... meet most electrophoresis needs in a personal, ... 150V power supply is capable of running ... designed for individuals to have his/her own ...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
Biology Products: